# STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

> **NCT00006343** · PHASE3 · COMPLETED · sponsor: **Novartis**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cytarabine
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00006343
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** — (—)
- **Last updated:** 2013-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006343, "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00006343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*